Novartis Q3 core EPS beats estimates, revenues slightly miss
FROM THE WIRE · FINANCE.YAHOO.COM
Swiss pharma giant Novartis AG NVS reported third-quarter 2026 core earnings per share (excluding one-time charges) of $2.46, which beat the Zacks Consensus Estimate of $2.25. The figure increased 9% from $2.25 reported a year ago. The bottom line benefited from the lower…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishCore EPS above estimates for a large pharma group, with the stock up in pre-market trading.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Core EPS was $2.46 versus $2.25 expected.
- 02Revenues of $14.52 billion missed consensus by about 0.2%.
- 03Priority brands Kisqali, Kesimpta, Scemblix and Leqvio supported sales.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets